Pulmonary hypertension (PH) is a multifactorial disease, commonly associated with heart failure. Different experimental models have emerged to help in the understanding of the molecular and cellular mechanisms associated with human PH, providing also a useful approach to test experimental therapies for PH treatment.
MCT effects require conversion to an active form (MCT pyrrole) in the liver by cytochrome P450, which makes the model dependent on the animals-based metabolic differences [4] . For instance, mice must be injected with the MCT pyrrole active form and not MCT itself. However, the disease development is far less extensive, stagnating in an acute lung injury [22] . Other animals less used are dogs [23] or pigs [24] , which can replicate human PAH more successfully than rodent models. Still, these kinds of animals are more expensive and the disease takes longer to develop [11] . In spite of the limitations of the MCT model, it is largely used once, in comparison with the other models, it is reproducible, less expensive and does not need particular technical skills [25] . Furthermore, it mimics human PH in terms of hemodynamic and histopathological severity, and high mortality [26] . 
Experimental models

Genetic Animal Models
In the past few years, numerous genetic animal models have emerged in the field of PH research [11, 13, 30] . The transgenic and knockout models allow the evaluation of the effect of overexpressing or downregulating a specific gene in the susceptibility to the development of PH. The high diversity of these models reflects the different molecular pathways underlying PH development [4, 9] . Even though there is not a clear separation, we can group the genetic models by the main processes that they interfere with: vascular tone and inflammation/vascular remodeling. Independently of the group, the most common specie used is the mouse, which is harder to handling in the experimental procedures, such as hemodynamic evaluation [11] . Inflammation is a key feature of PH pathogenesis, being already a therapeutic target [80, 81] . Genetic models are particularly useful for studying the effect of specific cytokines in PH pathophysiology. Among others, TNF-α [58] and TGF-α [57] overexpression is linked to PH. But, by far, the best studied models are the ones that target IL-6 related pathways. In fact, it is documented an increase in serum expression of IL-6 in patients with PAH, which positively correlates with the mortality rate [82, 83] . The mouse model of IL-6 overexpression was first implemented by Steiner et al. [54] . They found RV hypertrophy, an increased muscularization throughout the entire pulmonary vascular bed and the formation of occlusive neointimal angioproliferative lesions composed of endothelial cells and T-lymphocytes. Consistently, Savale et al. [84] found, in an IL-6 knockout model, diminished susceptibility to hypoxia-induced PH. They reported a decrease in media thickening of pulmonary vessels in IL-6 deficient mice and also a role of IL-6 in PASMC migration. Altogether, the IL-6 overexpressing mouse seems to be a model that resembles many of the pathologic features of PH. As a matter of fact, IL-6 has been proposed to regulate several pathways that are implicated in PH. It is believed that IL-6 drives the hyperproliferative state of PASMCs, modulates several pro-and anti-apoptotic factors [54] and the BMP signaling cascade [85] . Since a mutation of the BMPRII gene that encodes for the bone morphogenetic protein receptor II was discovered to be a principal mutation in hereditary PAH [86] , there have been attempts to create BMPRII-deficient mice. However, the complete deletion of the gene is incompatible with life and heterozygotes do not develop adequate disease severity [11] . This problem was overcome by the appearance of smooth muscle-specific transgenic mice expressing a dominant-negative BMPRII under control of a tetracycline gene switch system [60] . There is consistent evidence of the disease development in this model, namely an increase in RV systolic pressure, RV hypertrophy, an increase in muscularization of small pulmonary arteries and some blood flow changes [60, 87] . The BMPRII ligands are also targets of research in the field of PAH. BMP-2 and BMP-4 are the most important factors of this class and act in opposite ways in response to hypoxia: BMP-2 knockout mice have increase severity while the opposite happens with BMP-4 knockout mice [88] .
The protein S100A4/Mst1 is part of a family of calcium-binding proteins whose functions are related with cell proliferation, differentiation, cytoskeletal dynamics and apoptosis [4, 8] . Interestingly, the transgenic mice overexpressing S100A4/Mst1 model was initially developed aiming the study of S100A4/Mst1 role in metastatic cancer [89] . However, it was observed that approximately 5% of the S100A4/Mst1 overexpressing mice develop pulmonary vascular remodeling similar to that observed in PH [55] . Thus, the importance of this model in PH study is related with the presence of pulmonary vascular changes resembling human plexiform lesions, which is a feature absent in the majority of the PH models. Noteworthy, although the majority of the PH models show increased male susceptibility, contrary of what is observed in human PH; two genetic animal models (mice overexpressing the protein S100A4/Mts1 and mice overexpressing the serotonin transporter) showed a PH development female gender specific [90] . The fact that genetic models may not sum up all the complex features of PH, once they focus in the study of particular pathways is a limitation [11] . Furthermore, genetically modified mice are expensive, which may cause a limitation in the number of samples [91] .
Animal Models Involving Multiple Stimuli
Animal models that involve chronic hypoxia and MCT models have been developed aiming more severe PH and/or vascular lesions such as neointimal and plexiform lesions [92] . These occlusive lesions, which result from smooth muscle and endothelial cell proliferation, are hallmarks of Group 1 PH, being major contributors for the high pulmonary vascular resistance in PAH [93, 94] . However, they are absent in the most common single stimuli animal models. Those models that combine multiple insults result in more severe PH than single stimuli, suggesting that the pathogenesis of PH requires several insults [11] . SU5416 is a small molecule inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR-2). Given that VEGF is important for normal endothelial cell function, its blockade was expected to induce endothelial cell dysfunction, stimulate apoptosis-resistant endothelial cell proliferation and consequently cause PH [93] . Indeed, the SU5416/chronic hypoxia model is the most used multiple stimuli model to study both PH pathogenesis and treatment. Interestingly, this model demonstrated resistance to some drugs commonly used in PAH patients, being thus refractory to treatment as it is verified in most PAH patients [8, 93, 95] . However, a limitation of SU5416/chronic hypoxia model is the absence of perivascular inflammation, a key feature of human PAH [10, 11] . Another relevant multiple model consists in MCT administration coupled with pneumonectomy, which add to the MCT model vascular characteristics the presence of neointimal lesions [73] .
Nevertheless, it requires technical skills associated with the experimental procedure.
Conclusion and Future Perspectives
The complexity of the molecular mechanisms underlying PH pathogenesis and the diverse etiology that characterizes this disease makes the implementation of animal models a truly demanding task. Although a "gold"
animal model in PH research does not exist, there are several animal models available nowadays, each one presenting specific features of the disease, allowing the investigation of key aspects of the disease. These models are important not only for the discovery and exploration of the molecular pathways underlying disease pathogenesis but also for the assessment of therapeutic suitability to treat PH patients.
However, caution should be taken when translating data from animal models to the human context considering the different aspects of the disease in animal models. So, efforts should continue to be done in the development of animal models that more exactly mimic the features of each group of human PH. The current trend is the use of two animal models, such as MCT and chronic hypoxia, to demonstrate that data obtained are model independent and to facilitate data translation to the human clinical set. The simultaneous use of distinct PH animal models to test an experimental therapy is expected to continue and even increase once raises the hypothesis of its suitability for PH patients. 
